Shares surged more than 10% as Eli Lilly delivered what CEO Dave Ricks called an unprecedented streak: "Impressively, it's like our fifth or sixth quarter in a row posting really strong topline growth numbers." The question investors face now is whether a company trading at ~$940 — still 17% below its all-time high of $1,134 — has room to run, or whether falling drug prices will eventually cap the upside.
Volume Is Doing the Heavy Lifting While Prices Keep Dropping
Worldwide revenue hit $19.8 billion, an increase of 56%, driven by a 65% increase in volume, partially offset by a 13% decrease due to lower realized prices. That tradeoff matters: Lilly is selling far more prescriptions, but at cheaper price tags. Management still expects price to be a headwind "in the low to mid-teens" for the full year. Investors must watch whether Lilly can keep flooding the zone with enough patients to outrun those discounts — a math problem that only gets harder at scale.
The Obesity Pill Changes the Growth Calculus
The FDA approved Foundayo — the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions — which Lilly says "will meaningfully expand the number of people who can benefit from GLP-1s." Foundayo launched in Q2, so its revenue isn't in today's numbers. It was broadly available in pharmacies on April 9 and is on more than 12 major telehealth platforms, with commercial access confirmed at two of the three largest U.S. pharmacy benefit managers effective mid-May. This pill unlocks patients who won't use injections — a potentially massive new revenue stream layered on top of existing injectable sales.
Medicare Coverage Opens the Door to Millions of Seniors
CMS extended the Medicare GLP-1 Bridge program to begin no later than July 1, 2026, and run through December 2027, capping seniors' out-of-pocket costs at $50 per month. This is a direct demand accelerator: Ricks estimated global GLP-1 use will rise from approximately 20 million patients at the end of last year to 30 million at the end of 2026.
Raised Guidance Signals Management Is Still Playing Catch-Up With Demand
Lilly increased 2026 full-year revenue guidance to $82–$85 billion and non-GAAP EPS guidance to $35.50–$37.00.
At the midpoint, the revenue guidance lift represents a 2.5% increase, and the EPS raise represents a 5.8% bump — suggesting profits are growing faster than revenue thanks to operating margins expanding to 45%, up from 29% a year ago. With analysts' average 12-month price target at $1,219 — a 43% premium to current levels — the Street is betting this earnings machine has more gears to shift.